nach oben

Strahlentherapie und Onkologie

Erschienen in:

06.02.2016 | Review Article

Individualized radiotherapy by combining high-end irradiation and magnetic resonance imaging

verfasst von: Univ.-Prof. Dr. Stephanie E. Combs, Fridtjof Nüsslin, Jan J. Wilkens

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Image-guided radiotherapy (IGRT) has been integrated into daily clinical routine and can today be considered the standard especially with high-dose radiotherapy. Currently imaging is based on MV- or kV-CT, which has clear limitations especially in soft-tissue contrast. Thus, combination of magnetic resonance (MR) imaging and high-end radiotherapy opens a new horizon. The intricate technical properties of MR imagers pose a challenge to technology when combined with radiation technology. Several solutions that are almost ready for routine clinical application have been developed. The clinical questions include dose-escalation strategies, monitoring of changes during treatment as well as imaging without additional radiation exposure during treatment.

Lagendijk JJ, Raaymakers BW, van Vulpen M (2014) The magnetic resonance imaging-linac system. Semin Radiat Oncol 24:207–209CrossRefPubMed

Lagendijk JJ, Raaymakers B, van der Heide U, Overweg J, Brown K, Bakker C, Raaijmakers AJ, Vulpen M, Welleweerd J, Jurgenliemk-Schulz I (2005) In room magnetic resonance imaging guided radiotherapy_MRIgRT. Med Phys 32 2067

Dempsey JF, Benoit D, Fitzsimmons JR, Haghighat A, Li JG, Low DA, Mutic S, Palta JR, Romeijn HE, Sjoden GE A device for realtime 3D image-guided IMRT,” 47th Annual ASTRO General Meeting, Denver, CO, 2005, abstract _unpublished_. 47th Annual ASTRO General Meeting, Denver, CO, 2005. Abstract

Fallone BG (2014) The rotating biplanar linac-magnetic resonance imaging system. Semin Radiat Oncol 24:200–202CrossRefPubMed

Fallone BG et al (2009) First MR images obtained during megavoltage photon irradiation from a prototype integrated linac-MR system. Med Phys 36:2084–2088CrossRefPubMed

Lagendijk JJ et al (2014) MR guidance in radiotherapy. Phys Med Biol 59:R349–R369CrossRefPubMed

Menard C, van der Heide U (2014) Introduction: systems for magnetic resonance image guided radiation therapy. Semin Radiat Oncol 24:192CrossRefPubMed

Mutic S, Dempsey JF (2014) The ViewRay system: magnetic resonance-guided and controlled radiotherapy. Semin Radiat Oncol 24:196–199CrossRefPubMed

Jaffray DA et al (2014) A facility for magnetic resonance-guided radiation therapy. Semin Radiat Oncol 24:193–195CrossRefPubMed

10.

Lagendijk JJ et al (2008) MRI/linac integration. Radiother Oncol 86:25–29CrossRefPubMed

11.

Keall PJ et al (2014) The Australian magnetic resonance imaging-linac program. Semin Radiat Oncol 24:203–206CrossRefPubMed

12.

Raaijmakers AJ, Raaymakers BW, Lagendijk JJ (2008) Magnetic-field-induced dose effects in MR-guided radiotherapy systems: dependence on the magnetic field strength. Phys Med Biol 53:909–923CrossRefPubMed

13.

Raaijmakers AJ, Raaymakers BW, Lagendijk JJ (2005) Integrating a MRI scanner with a 6 MV radiotherapy accelerator: dose increase at tissue-air interfaces in a lateral magnetic field due to returning electrons. Phys Med Biol 50:1363–1376CrossRefPubMed

14.

Nischwitz SP et al (2015) Clinical implementation and range evaluation of in vivo PET dosimetry for particle irradiation in patients with primary glioma. Radiother Oncol 115:179–185CrossRefPubMed

15.

Rieken S et al (2013) Analysis of FET-PET imaging for target volume definition in patients with gliomas treated with conformal radiotherapy. Radiother Oncol 109:487–492CrossRefPubMed

16.

Afshar-Oromieh A et al (2015) Comparison of (6)(8)Ga-DOTATOC-PET/CT and PET/MRI hybrid systems in patients with cranial meningioma: initial results. Neuro Oncol 17:312–319CrossRefPubMedPubMedCentral

17.

Fuss M et al (2000) Radiation-induced regional cerebral blood volume (rCBV) changes in normal brain and low-grade astrocytomas: quantification and time and dose-dependent occurrence. Int J Radiat Oncol Biol Phys 48:53–58CrossRefPubMed

18.

Wenz F et al (1996) Effect of radiation on blood volume in low-grade astrocytomas and normal brain tissue: quantification with dynamic susceptibility contrast MR imaging. AJR Am J Roentgenol 166:187–193CrossRefPubMed

19.

Ravn S et al (2013) Differences in supratentorial white matter diffusion after radiotherapy—new biomarker of normal brain tissue damage? Acta Oncol 52:1314–1319CrossRefPubMed

20.

Bondiau PY et al (2011) Biocomputing: numerical simulation of glioblastoma growth and comparison with conventional irradiation margins. Phys Med 27:103–108CrossRefPubMed

21.

Ratai EM et al (2013) Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677. Neuro Oncol 15:936–944CrossRefPubMedPubMedCentral

22.

Sottoriva A et al (2013) Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A 110:4009–4014CrossRefPubMedPubMedCentral

23.

Muruganandham M et al (2014) 3-Dimensional magnetic resonance spectroscopic imaging at 3 T for early response assessment of glioblastoma patients during external beam radiation therapy. Int J Radiat Oncol Biol Phys 90:181–189CrossRefPubMedPubMedCentral

24.

Berberat J et al (2014) Diffusion tensor imaging for target volume definition in glioblastoma multiforme. Strahlenther Onkol 190:939–943CrossRefPubMed

25.

Konukoglu E et al (2010) Image guided personalization of reaction-diffusion type tumor growth models using modified anisotropic eikonal equations. IEEE Trans Med Imaging 29:77–95CrossRefPubMed

26.

Trepanier PY et al (2012) A Monte Carlo based formalism to identify potential locations at high risk of tumor recurrence with a numerical model for glioblastoma multiforme. Med Phys 39:6682–6691CrossRefPubMed

27.

Mazzola R et al (2014) Dose-volume-related dysphagia after constrictor muscles definition in head and neck cancer intensity-modulated radiation treatment. Br J Radiol 87:20140543CrossRefPubMedPubMedCentral

28.

Bijl HP et al (2003) Unexpected changes of rat cervical spinal cord tolerance caused by inhomogeneous dose distributions. Int J Radiat Oncol Biol Phys 57:274–281CrossRefPubMed

29.

Konings AW et al (2006) Secondary radiation damage as the main cause for unexpected volume effects: a histopathologic study of the parotid gland. Int J Radiat Oncol Biol Phys 64:98–105CrossRefPubMed

30.

Nielsen TB et al (2014) Inhomogeneous dose escalation increases expected local control for NSCLC patients with lymph node involvement without increased mean lung dose. Acta Oncol 53:119–125CrossRefPubMed

31.

van Elmpt W et al (2012) The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. Radiother Oncol 104:67–71CrossRefPubMed

32.

Lordick F et al (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8:797–805CrossRefPubMed

33.

zum Buschenfelde CM et al (2011) (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. J Nucl Med 52:1189–1196CrossRef

34.

Warren S et al (2014) Radiobiological determination of dose escalation and normal tissue toxicity in definitive chemoradiation therapy for esophageal cancer. Int J Radiat Oncol Biol Phys 90:423–429CrossRefPubMedPubMedCentral

35.

Gkika E et al (2014) Long-term results of definitive radiochemotherapy in locally advanced cancers of the cervical esophagus. Dis Esophagus 27:678–684CrossRefPubMed

36.

Freilich J et al (2015) Comparative outcomes for three-dimensional conformal versus intensity-modulated radiation therapy for esophageal cancer. Dis Esophagus 28:352–357CrossRefPubMed

37.

van Hagen P et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074–2084CrossRefPubMed

38.

Darby SC et al (2013) Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368:987–998CrossRefPubMed

39.

Marks LB et al (2005) The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys 63:214–223CrossRefPubMed

40.

Graeff C, Durante M, Bert C (2012) Motion mitigation in intensity modulated particle therapy by internal target volumes covering range changes. Med Phys 39:6004–6013CrossRefPubMed

41.

Bert C, Durante M (2011) Motion in radiotherapy: particle therapy. Phys Med Biol 56:R113–R144CrossRefPubMed

42.

Naumann P et al (2013) Outcome after neoadjuvant chemoradiation and correlation with nutritional status in patients with locally advanced pancreatic cancer. Strahlenther Onkol 189:745–752CrossRefPubMed

43.

Combs SE et al (2013) Intensity modulated radiotherapy as neoadjuvant chemoradiation for the treatment of patients with locally advanced pancreatic cancer. Outcome analysis and comparison with a 3D-treated patient cohort. Strahlenther Onkol 189:738–744CrossRefPubMed

44.

Benson AB 3rd et al (2012) Rectal cancer. J Natl Compr Canc Netw 10:1528–1564PubMed

45.

Maas M et al (2011) Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol 29:4633–4640CrossRefPubMed

46.

Glynne-Jones R, Tan D, Goh V (2014) Pelvic MRI for guiding treatment decisions in rectal cancer. Oncology (Williston Park) 28:667–677

47.

Bartram C, Brown G (2002) Endorectal ultrasound and magnetic resonance imaging in rectal cancer staging. Gastroenterol Clin North Am 31:827–839CrossRefPubMed

48.

Burbach JP et al (2014) Impact of radiotherapy boost on pathological complete response in patients with locally advanced rectal cancer: a systematic review and meta-analysis. Radiother Oncol 113:1–9CrossRefPubMed

49.

Heuck A et al (2003) [MR imaging of prostate cancer]. Radiologe 43:464–473CrossRefPubMed

50.

Schiller K et al (2014) Impact of different setup approaches in image-guided radiotherapy as primary treatment for prostate cancer: a study of 2940 setup deviations in 980 MVCTs. Strahlenther Onkol 190:722–726CrossRefPubMed

51.

Habl G et al (2014) Ion Prostate Irradiation (IPI)—a pilot study to establish the safety and feasibility of primary hypofractionated irradiation of the prostate with protons and carbon ions in a raster scan technique. BMC Cancer 14:202CrossRefPubMedPubMedCentral

52.

Schmidt MA, Payne GS (2015) Radiotherapy planning using MRI. Phys Med Biol 60:R323–R361CrossRefPubMed

53.

Dowling JA et al (2012) An atlas-based electron density mapping method for magnetic resonance imaging (MRI)-alone treatment planning and adaptive MRI-based prostate radiation therapy. Int J Radiat Oncol Biol Phys 83:e5–e11CrossRefPubMed

54.

Uh J et al (2014) MRI-based treatment planning with pseudo CT generated through atlas registration. Med Phys 41:051711CrossRefPubMed

55.

Korhonen J et al (2014) A dual model HU conversion from MRI intensity values within and outside of bone segment for MRI-based radiotherapy treatment planning of prostate cancer. Med Phys 41:011704CrossRefPubMed

56.

Jonsson JH et al (2013) Treatment planning of intracranial targets on MRI derived substitute CT data. Radiother Oncol 108:118–122CrossRefPubMed

57.

Hissoiny S et al (2011) Fast dose calculation in magnetic fields with GPUMCD. Phys Med Biol 56:5119–5129CrossRefPubMed

58.

Yang YM, Bednarz B (2013) Consistency evaluation between EGSnrc and Geant4 charged particle transport in an equilibrium magnetic field. Phys Med Biol 58:N47–N58CrossRefPubMed

59.

St Aubin J, Keyvanloo A, Vassiliev O et al (2015) A deterministic solution of the first order linear Boltzmann transport equation in the presence of external magnetic fields. Med Phys 42:780–793CrossRefPubMed

60.

Raaijmakers AJ et al (2007) Dose optimization for the MRI-accelerator: IMRT in the presence of a magnetic field. Phys Med Biol 52:7045–7054CrossRefPubMed

61.

Rausch M, Schyboll F, Neeb H (2013) First Measurement of signale changes induced by ionizing radiation in magnetic resonance imaging. TM Technisches Messen 80:397–403CrossRef

62.

Moteabbed M, Schuemann J, Paganetti H (2014) Dosimetric feasibility of real-time MRI-guided proton therapy. Med Phys 41:111713CrossRefPubMedPubMedCentral

63.

Hartman J et al (2015) Dosimetric feasibility of intensity modulated proton therapy in a transverse magnetic field of 1.5 T. Phys Med Biol 60:5955–5969CrossRefPubMed

Titel: Individualized radiotherapy by combining high-end irradiation and magnetic resonance imaging
verfasst von: Univ.-Prof. Dr. Stephanie E. Combs
Fridtjof Nüsslin
Jan J. Wilkens
Publikationsdatum: 06.02.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 4/2016
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-016-0944-5

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Individualized radiotherapy by combining high-end irradiation and magnetic resonance imaging

Abstract

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

GILT—A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer

Prostate cancer treated with image-guided helical TomoTherapy® and image-guided LINAC-IMRT

Setup accuracy for prone and supine whole breast irradiation

Unilateral and bilateral neck SIB for head and neck cancer patients

Postoperative Radiotherapie des Endometriumkarzinoms

Bestrahlung der Mammaria-interna-Lymphknoten beim frühen nodalpositiven Mammakarzinom

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie